Cargando…
A Micro-Configured Multiparticulate Reconstitutable Suspension Powder of Fixed Dose Rifampicin and Pyrazinamide: Optimal Fabrication and In Vitro Quality Evaluation
The scarcity of age-appropriate pharmaceutical formulations is one of the major challenges impeding successful management of tuberculosis (TB) prevalence in minors. To this end, we designed and assessed the quality of a multiparticulate reconstitutable suspension powder containing fixed dose rifampi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861895/ https://www.ncbi.nlm.nih.gov/pubmed/36678693 http://dx.doi.org/10.3390/pharmaceutics15010064 |
_version_ | 1784874956144771072 |
---|---|
author | Rampedi, Penelope N. Ogunrombi, Modupe O. Wesley-Smith, James Adeleke, Oluwatoyin A. |
author_facet | Rampedi, Penelope N. Ogunrombi, Modupe O. Wesley-Smith, James Adeleke, Oluwatoyin A. |
author_sort | Rampedi, Penelope N. |
collection | PubMed |
description | The scarcity of age-appropriate pharmaceutical formulations is one of the major challenges impeding successful management of tuberculosis (TB) prevalence in minors. To this end, we designed and assessed the quality of a multiparticulate reconstitutable suspension powder containing fixed dose rifampicin and pyrazinamide (150 mg/300 mg per 5 mL) which was prepared employing solid–liquid direct dispersion coupled with timed dehydration, and mechanical pulverization. The optimized formulation had a high production yield (96.000 ± 3.270%), displayed noteworthy powder flow quality (9.670 ± 1.150°), upon reconstitution the suspension flow property was non-Newtonian and was easily redispersible with gentle manual agitation (1.720 ± 0.011 strokes/second). Effective drug loading was attained for both pyrazinamide (97.230 ± 2.570%w/w) and rifampicin (97.610 ± 0.020%w/w) and drug release followed a zero-order kinetic model (R(2) = 0.990) for both drugs. Microscopic examinations confirmed drug encapsulation efficiency and showed that the particulates were micro-dimensional in nature (n < 700.000 µm). The formulation was physicochemically stable with no chemically irreversible drug-excipient interactions based on the results of characterization experiments performed. Findings from organoleptic evaluations generated an overall rating of 4.000 ± 0.000 for its attractive appearance and colour 5.000 ± 0.000 confirming its excellent taste and extremely pleasant smell. Preliminary cytotoxicity studies showed a cell viability above 70.000% which indicates that the FDC formulation was biocompatible. The optimized formulation was environmentally stable either as a dry powder or reconstituted suspension. Accordingly, a stable and palatable FDC antimycobacterial reconstitutable oral suspension powder, intended for flexible dosing in children and adolescents, was optimally fabricated. |
format | Online Article Text |
id | pubmed-9861895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98618952023-01-22 A Micro-Configured Multiparticulate Reconstitutable Suspension Powder of Fixed Dose Rifampicin and Pyrazinamide: Optimal Fabrication and In Vitro Quality Evaluation Rampedi, Penelope N. Ogunrombi, Modupe O. Wesley-Smith, James Adeleke, Oluwatoyin A. Pharmaceutics Article The scarcity of age-appropriate pharmaceutical formulations is one of the major challenges impeding successful management of tuberculosis (TB) prevalence in minors. To this end, we designed and assessed the quality of a multiparticulate reconstitutable suspension powder containing fixed dose rifampicin and pyrazinamide (150 mg/300 mg per 5 mL) which was prepared employing solid–liquid direct dispersion coupled with timed dehydration, and mechanical pulverization. The optimized formulation had a high production yield (96.000 ± 3.270%), displayed noteworthy powder flow quality (9.670 ± 1.150°), upon reconstitution the suspension flow property was non-Newtonian and was easily redispersible with gentle manual agitation (1.720 ± 0.011 strokes/second). Effective drug loading was attained for both pyrazinamide (97.230 ± 2.570%w/w) and rifampicin (97.610 ± 0.020%w/w) and drug release followed a zero-order kinetic model (R(2) = 0.990) for both drugs. Microscopic examinations confirmed drug encapsulation efficiency and showed that the particulates were micro-dimensional in nature (n < 700.000 µm). The formulation was physicochemically stable with no chemically irreversible drug-excipient interactions based on the results of characterization experiments performed. Findings from organoleptic evaluations generated an overall rating of 4.000 ± 0.000 for its attractive appearance and colour 5.000 ± 0.000 confirming its excellent taste and extremely pleasant smell. Preliminary cytotoxicity studies showed a cell viability above 70.000% which indicates that the FDC formulation was biocompatible. The optimized formulation was environmentally stable either as a dry powder or reconstituted suspension. Accordingly, a stable and palatable FDC antimycobacterial reconstitutable oral suspension powder, intended for flexible dosing in children and adolescents, was optimally fabricated. MDPI 2022-12-25 /pmc/articles/PMC9861895/ /pubmed/36678693 http://dx.doi.org/10.3390/pharmaceutics15010064 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rampedi, Penelope N. Ogunrombi, Modupe O. Wesley-Smith, James Adeleke, Oluwatoyin A. A Micro-Configured Multiparticulate Reconstitutable Suspension Powder of Fixed Dose Rifampicin and Pyrazinamide: Optimal Fabrication and In Vitro Quality Evaluation |
title | A Micro-Configured Multiparticulate Reconstitutable Suspension Powder of Fixed Dose Rifampicin and Pyrazinamide: Optimal Fabrication and In Vitro Quality Evaluation |
title_full | A Micro-Configured Multiparticulate Reconstitutable Suspension Powder of Fixed Dose Rifampicin and Pyrazinamide: Optimal Fabrication and In Vitro Quality Evaluation |
title_fullStr | A Micro-Configured Multiparticulate Reconstitutable Suspension Powder of Fixed Dose Rifampicin and Pyrazinamide: Optimal Fabrication and In Vitro Quality Evaluation |
title_full_unstemmed | A Micro-Configured Multiparticulate Reconstitutable Suspension Powder of Fixed Dose Rifampicin and Pyrazinamide: Optimal Fabrication and In Vitro Quality Evaluation |
title_short | A Micro-Configured Multiparticulate Reconstitutable Suspension Powder of Fixed Dose Rifampicin and Pyrazinamide: Optimal Fabrication and In Vitro Quality Evaluation |
title_sort | micro-configured multiparticulate reconstitutable suspension powder of fixed dose rifampicin and pyrazinamide: optimal fabrication and in vitro quality evaluation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861895/ https://www.ncbi.nlm.nih.gov/pubmed/36678693 http://dx.doi.org/10.3390/pharmaceutics15010064 |
work_keys_str_mv | AT rampedipenelopen amicroconfiguredmultiparticulatereconstitutablesuspensionpowderoffixeddoserifampicinandpyrazinamideoptimalfabricationandinvitroqualityevaluation AT ogunrombimodupeo amicroconfiguredmultiparticulatereconstitutablesuspensionpowderoffixeddoserifampicinandpyrazinamideoptimalfabricationandinvitroqualityevaluation AT wesleysmithjames amicroconfiguredmultiparticulatereconstitutablesuspensionpowderoffixeddoserifampicinandpyrazinamideoptimalfabricationandinvitroqualityevaluation AT adelekeoluwatoyina amicroconfiguredmultiparticulatereconstitutablesuspensionpowderoffixeddoserifampicinandpyrazinamideoptimalfabricationandinvitroqualityevaluation AT rampedipenelopen microconfiguredmultiparticulatereconstitutablesuspensionpowderoffixeddoserifampicinandpyrazinamideoptimalfabricationandinvitroqualityevaluation AT ogunrombimodupeo microconfiguredmultiparticulatereconstitutablesuspensionpowderoffixeddoserifampicinandpyrazinamideoptimalfabricationandinvitroqualityevaluation AT wesleysmithjames microconfiguredmultiparticulatereconstitutablesuspensionpowderoffixeddoserifampicinandpyrazinamideoptimalfabricationandinvitroqualityevaluation AT adelekeoluwatoyina microconfiguredmultiparticulatereconstitutablesuspensionpowderoffixeddoserifampicinandpyrazinamideoptimalfabricationandinvitroqualityevaluation |